Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
Status:
Completed
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy
when there is no vaccine or treatment available for infectious diseases. In the latest viral
epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization
issued a document outlining a protocol for the use of whole blood or plasma collected from
patients who have recovered from the Ebola virus disease by transfusion to empirically treat
local infectious outbreaks
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Universidad del Rosario
Collaborators:
CES University Fundación Universitaria de Ciencias de la Salud Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud